6,000 new jobs in Novo Nordisk create a further 15,000 jobs in Denmark
Up to 2022, Novo Nordisk expects to hire 6,000 new
employees in Denmark, half of whom will work within research and development. The new jobs will have the derived effect of boosting employment by more than 15,000 jobs
nationally. This is revealed by a new analysis to be presented by Novo Nordisk today at the 'Invitation to growth - a road to job creation' conference. The analysis homes in on the value created in the interaction between growth businesses and public-sector research and education, as well as the challenges that must be solved so that research-based businesses can continue to grow in Denmark. 
AstraZeneca has announced its intention to collaborate with the Medical Research Council Laboratory of Molecular Biology (MRC LMB) to fund a range of pre-clinical research projects aimed at better understanding the biology of disease. Projects supported by the fund are likely to involve scientists from the two organisations working side by side, either within the MRC LMB at the Cambridge Biomedical Campus, the site of the company's future strategic R&D centre and global corporate headquarters, or in AstraZeneca and MedImmune research facilities. 
Novartis, the global leader in eye care, is calling for the eXcellence in Ophthalmology Vision Award (XOVA), co-sponsored by Alcon and Novartis Pharmaceuticals. The XOVA, launched in 2010, provides funding to projects worldwide that support initiatives that help deliver sustained improvements in eye care globally. It is open to all eye care specialists, including trainees and specialist nurses and grant funding will be provided to the employing institution of the winning applicant. 
A pioneering public-private research initiative between GSK, the European Bioinformatics Institute (EMBL-EBI) and the Wellcome Trust Sanger Institute is to harness the power of 'big data' and genome sequencing to improve the success rate for discovering new medicines. The new Centre for Therapeutic Target Validation (CTTV) will aim to address a wide range of human diseases and will share its data openly in the interests of accelerating drug discovery. The CTTV aims to use the almost daily advances in cutting-edge genetic research to help researchers in that crucial first step in exploring new medicines - finding where to start. Target validation is about clearly defining the role that a biological process plays in disease before developing a new drug to tackle it. 
A new online, interactive training programme designed to help patient advocates better influence decisions related to access to new medicines was launched today in advance of the 6th Global Patient Congress at Ascot, United Kingdom. Developed by Eli Lilly and Company in collaboration with internationally renowned experts in the fields of patient involvement and health technology assessment (HTA), the eMEET (Medicine Evaluation Educational Training) online resource is a unique tool designed to help patient advocates navigate the complex world of medicines development, evaluation and assessment. eMEET is endorsed by Health Technology Assessment International (HTAi), the global scientific and professional society for those who produce, use, or encounter HTA.(1)